Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024

SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., July 1, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented the clinical data and single-cell an...

2024-07-01 15:43 2298

Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA

NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces thatthe investigational new d...

2024-06-28 18:59 2808

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-06-27 07:08 3136

bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention

NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded inSan Diego, spanning from Jun...

2024-06-26 21:00 2343

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase2b trial SYDNEY, ...

2024-06-26 20:56 3349

Fufang E'jiao Syrup's Breakthrough Research on Cancer-Related Fatigue Receives "Special Excellence Award" at 2024 ASCO Annual Meeting

CHICAGO, June 26, 2024 /PRNewswire/ -- The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), a significant event in the global oncology community, was grandly held inChicago, USA, from May 31 to June 4, 2024. ASCO has announced the list of outstanding abstracts for 2024, wh...

2024-06-26 18:42 2286

Fufang E'jiao Syrup's Breakthrough Research on Cancer-Related Fatigue Receives

Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EG...

2024-06-26 12:36 3020

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 3071

ONO PHARMA USA Announces Support for Conquer Cancer®, the ASCO Foundation

Conquer Cancer Supports Cancer Research and Education CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- ONO PHARMA USA today announced it will provide a sponsorship to Conquer Cancer®, the ASCO Foundation, with$1 million funding to advance cancer research and education. Conquer Cancer is a glob...

2024-06-25 21:00 2195

Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. T...

2024-06-25 20:00 3199

Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services

NX Group Signs Strategic Partnership Agreement with Controlant of Iceland

- Set to Provide Real-time Monitoring Service for Tracking Cargo Location and Strict Temperature Control - TOKYO, June 25, 2024 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. has signed a strategic partnership agreement withIceland-based Controlant, Inc., a leading provider of real-time monitorin...

2024-06-25 14:00 2372

TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-lifein a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors * TiumBio presented interim Phase 1a clinical data of TU7710 and discussed pot...

2024-06-24 20:00 2942

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for T...

2024-06-20 14:51 2512

GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group

* GC Cell and PT Bifarma Adiluhung announced a strategic partnership to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for HCC into the Indonesian market. YONGIN, South Korea, June 19, 2024 /PRNewswire/ --GC Cell , a fully inte...

2024-06-20 08:44 4178

GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. * Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/...

2024-06-19 19:30 3294

GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation

SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in...

2024-06-19 19:00 2930

Diabetes Researchers in China Demonstrate Early Insulin Therapy Significant Benefits Cardiovascular Health

BEIJING, June 19, 2024 /PRNewswire/ -- Recently, Professor Jianping Weng of the University of Science and Technology ofChina (USTC) and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their lat...

2024-06-19 18:10 2203

Tang Prize in Biopharmaceutical Science Honoring Three Scientists

TAIPEI, June 19, 2024 /PRNewswire/ -- In a continuing series of laureate announcements, the Tang Prize Foundationtoday (June 19th) announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded toJoel F. Habener, Svetlana Mojsov, and Jens Juu...

2024-06-19 12:15 3734

Tang Prize in Biopharmaceutical Science Honoring Three Scientists

YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China

Strategic Partnership to Advance Gene Editing Technologies in Biomedical Applications SHANGHAI, June 18, 2024 /PRNewswire/ -- YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery forin vivo gene editing therapies, has partnered with KACTUS, a leading developer se...

2024-06-19 09:00 2644

ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals

BRISBANE, Calif. and SHANGHAI, June 17, 2024 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncology indications, and Asieris Pharmaceuticals, a global biopharmaceutical leader in ...

2024-06-17 22:00 3773

1 ... 77 78 798081 82 83 ... 164